Description
The global preimplantation genetic testing market was valued at USD 934.3 million in 2025 and is projected to reach at USD 1.8 billion by 2032, expanding at a CAGR of 9.4% from 2026 to 2032. Preimplantation genetic testing (PGT) is an advanced genetic screening technique performed during in vitro fertilization (IVF) to evaluate embryos for chromosomal abnormalities, monogenic disorders, and structural chromosomal rearrangements prior to embryo implantation. The market comprises products, services, and software supporting preimplantation genetic testing procedures utilizing technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and single nucleotide polymorphism (SNP) arrays. Increasing infertility rates, rising prevalence of inherited genetic disorders, growing awareness regarding reproductive health, and expanding utilization of assisted reproductive technologies (ART) are significantly driving market adoption across fertility clinics, hospitals, diagnostic laboratories, and research institutions worldwide.
Market growth is further supported by continuous technological advancements in genomic sequencing, increasing success rates of IVF procedures, favorable reimbursement initiatives in selected countries, and rising acceptance of genetic screening among prospective parents. Healthcare providers are increasingly incorporating comprehensive embryo screening to improve implantation success, reduce miscarriage rates, and minimize the risk of transmitting hereditary diseases. Advancements in AI-assisted embryo selection, automation of genetic analysis, high-throughput sequencing platforms, and improved laboratory workflows are enhancing testing accuracy while reducing turnaround times. In addition, increasing investments in reproductive medicine, expanding fertility tourism, and growing availability of personalized reproductive healthcare solutions are expected to create new growth opportunities. North America currently dominates the global market owing to widespread adoption of advanced reproductive technologies, while Asia Pacific is anticipated to witness the fastest expansion due to improving fertility care infrastructure and rising healthcare expenditure.
Key Highlights of the Report
• By offering, products dominate the global preimplantation genetic testing market, driven by the continuous demand for reagents, sequencing kits, consumables, and laboratory instruments required for embryo genetic analysis.
• The services segment is projected to witness the fastest growth, supported by increasing outsourcing of genetic testing procedures, growing adoption of specialized laboratory services, and expanding IVF treatment volumes.
• By procedure, preimplantation genetic testing for aneuploidy (PGT-A) dominates the global market, owing to its widespread use in identifying chromosomal abnormalities and improving IVF success rates.
• Preimplantation genetic testing for monogenic disorders (PGT-M) is expected to register the fastest growth, driven by increasing awareness of inherited genetic disorders and growing utilization among high-risk families.
• By technology, next-generation sequencing (NGS) accounts for the largest market share, supported by superior accuracy, comprehensive chromosomal analysis, high-throughput capability, and increasing clinical adoption.
• NGS is also anticipated to be the fastest-growing technology segment, replacing conventional molecular testing approaches due to continuous technological advancements and declining sequencing costs.
• By application, aneuploidy screening dominates the global preimplantation genetic testing market, reflecting the increasing need to improve embryo selection and reduce implantation failure during assisted reproductive procedures.
• Genetic disease screening is projected to experience significant growth, owing to rising incidence of hereditary disorders and increasing utilization of personalized reproductive medicine.
• By end use, fertility clinics dominate the market, supported by growing IVF procedure volumes, increasing availability of advanced embryo screening technologies, and expanding fertility treatment services worldwide.
• Hospitals and diagnostic laboratories are expected to witness robust growth, driven by expanding reproductive healthcare infrastructure and increasing adoption of molecular diagnostic technologies.
• The increasing prevalence of infertility remains one of the primary market growth drivers, encouraging couples to seek assisted reproductive technologies integrated with advanced genetic screening.
• Continuous advancements in genomic technologies are improving diagnostic precision, enabling more comprehensive embryo assessment while supporting personalized fertility treatment strategies.
• Growing awareness regarding inherited genetic disorders and reproductive health is encouraging broader adoption of preimplantation genetic testing, particularly among couples with known genetic risks.
• By region, North America dominates the global preimplantation genetic testing market, supported by advanced fertility treatment infrastructure, high healthcare expenditure, widespread utilization of IVF procedures, and favorable regulatory frameworks.
• Asia Pacific is projected to be the fastest-growing regional market, driven by expanding fertility clinic networks, increasing infertility prevalence, improving healthcare infrastructure, and growing investments in reproductive medicine.
• Europe represents a significant regional market, supported by increasing utilization of assisted reproductive technologies, rising awareness of genetic disorders, and continuous advancements in reproductive healthcare.
• The competitive landscape is moderately consolidated, with leading companies focusing on genomic technology innovation, strategic collaborations, laboratory expansion, and product portfolio enhancement to strengthen their market presence.
Key Company Profiles
• Agilent Technologies
• Fulgent Genetics
• Genea BIOMEDX
• Illumina
• Medicover Genetics
• Natera
• Revvity
• RGI
• Thermo Fisher Scientific
• Varinos
Data Source
Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.
